Search

From novice to overnight on-calls: developing an ophthalmology bootcamp to ease the learning curve for new trainees

Introduction My first ophthalmology on-call was nine years ago and it was a fairly traumatic experience. I was an FY2 in a Welsh district general hospital and I was on my own – at least, that’s how it felt to...

Investigating the link between corneal clarity and statin use

Transparency is a vital attribute of the cornea, necessary in preserving healthy vision. Maintaining this requires the collective input of the various layers of the cornea. Mostly, the layers implicated in this are the corneal stroma and endothelium [1]. Our...

Glaucoma: 30 years on

Back in 1993, the late and great Barry Cullen FRCS (Cavan born, Dublin trained), the first editor of Eye News, asked me to write an article about the current treatment of chronic open angle glaucoma (COAG). At the time I...

Part 2: the Arclight Device: frugal imaging for eyecare

In this three-part series (Click here for Part 1) Andrew Blaikie and his team explore the role and application of the Arclight Device in Imaging of the Eye. There are many different types of ophthalmic imaging tools; from simply taking...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....

Pathophysiology of diabetic macular oedema: why combination therapy may be better

The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...